OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Issue Information	159
	142
PoDCall: a robust tool for automated droplet classification in DNA‐methylation droplet digital PCR	120
	96
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”	91
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer	86
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with	85
Precision Cancer Medicine 2.0—Oncology in the postgenomic era	79
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis	76
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”	74
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation	59
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma	59
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy	51
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo	42
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer	39
Microglia limit brain tumor development by restricting tumor cell proliferation and inducing T‐cell immunity	38
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection	37
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4	35
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system	34
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities	33
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer	33
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy	33
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 ⁺ mononuc	32
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐	32
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1	32

Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity	31
Issue Information	31
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer	30
Unraveling LINE ‐1 retrotransposition in head and neck squamous cell carcinoma	29